Русский / English
Enter the query
Petrovax Pharm
16,9 mln
doses of flu vaccine supplied to Russia’s regions

NPO Petrovax Pharm is a leading research and manufacturing company in Russia, producing pharmaceuticals and vaccines. Interros acquired a controlling stake in the company in 2013.

The company was founded in 1996 by a team of Russian researchers to develop, produce and commercialize original innovative pharmaceuticals.

The company’s main areas of focus are manufacturing flu vaccine to meet the national immunization calendar, and developing and producing immunobiologicals and long-acting nanobio drugs.

The company’s product line consists exclusively of innovative drugs and vaccines that NPO Petrovax Pharm successfully markets in Russia and the countries of the CIS and the EU.

CEO: Arkady Nekrasov

2 Dnepropetrovskaya st., Commercial Center Global City
Moscow, 117587, Russia

Tel: +7 (495) 984 2753
Fax: +7 (495) 984 2754 

History
2013
13.3 mln doses
of flu vaccine supplied to Russia’s regions
In accordance with the National Immunization Calendar, NPO Petrovax Pharm supplies 13.3 mln doses of Grippol® Plus vaccine. The primary vaccine recipients are the regions in the Far East Federal District that had experienced flooding: Khabarovsk Kray and the Amur and Jewish autonomous regions.

Working with Pfizer, NPO Petrovax Pharm implements a fully integrated production cycle to manufacture, monitor, and ensure quality control of the 13-valent pneumococcal conjugate vaccine, and produces the first few commercial batches. 

Over the course of the year, the company organizes a number of philanthropic initiatives. Together with Pfizer, it supports the Rostropovich-Vishnevskaya Foundation’s For the Health & Future of Children Program. Petrovax Pharm sends assistance to the flooded regions in the Far East Federal District and organizes a blood drive in conjunction with the Hematology Research Center’s Free Blood Donation Program.

The company begins work on a new development strategy. At the end of the year, Interros Holding enters into an agreement with NPO Petrovax Pharm to acquire a controlling stake in the company.
More
History
2014
16.9 mln doses
will be shipped to regionals with framework of the National Immunisation Schedule
The company of Vladimir Potanin, founder of the Interros Group, finalizes the acquisition of the controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company.
More
History
2015
>20 mln doses
vaccines against flue and pneumococcus Petrovax will produce in 2015
Will be shipped to regionals with framework of National Immunisation Schedule.
More
History
2016
Localized production of the Grippol® Plus flu vaccine in Belarus

February: Petrovax Pharm signs a trilateral strategic cooperation agreement in order to localize production of the Russian flu vaccine Grippol® Plus in Iran.

Petrovax Pharm launches Imoferaza®, an innovative ointment to treat problem areas and scar tissue after injuries, burns, acne, surgeries, and cosmetic procedures.

June: Petrovax Pharm and the German firm Boehringer Ingelheim sign an agreement to localize in Russia the full production cycle of state-of-the-art medicines for cardiovascular diseases.

July: Petrovax Pharm receives a Russian GMP compliance certificate following a directive of the Russian Federation Ministry of Industry and Trade.

August: Petrovax Pharm exports 1.5 million doses of Grippol® Plus flu vaccine to Kazakhstan.

October: Petrovax Pharm supplies more than 8.5 million doses of pediatric Grippol® Plus flu vaccine to meet the National Vaccination Schedule of the Russian Federation.

Polyoxidoniy, manufactured by Petrovax Pharm, receives a 2016 Russian Pharma Award for best pediatric immunity booster for acute upper respiratory infections.

Petrovax Pharm supplies 1.5 million doses of Grippol® Plus to Kazakhstan under the national drug and medical supplies procurement program.

More
History
2017
11 countries
import products manufactured by the company

At the beginning of the year NPO Petrovax Pharm invested over 900 million rubles in a new production line that meets all GMP requirements, allowing a two-and-a-half-fold increase in the production of pharmaceutical substances, a seven-fold increase in the production of pills, and a quadrupling of its suppositories production capacity.


In March, NPO Petrovax Pharm was again certified by the Ministry of Industry and Trade as having a manufacturing and management systems compliant with the GMP quality requirements, thus confirming that the company meets their high standards. Soon after, Petrovax Pharm announced an extension of the recommended age group for the use of Polyoxidonium ® to include children starting at 3 years old.


In June, under the sponsorship of NPO Petrovax Pharm and the Interros Group, the country-wide scientific forum «Days of Immunology in Saint Petersburg» held its sixteenth session in Saint-Petersburg.


In July, the company received a report on the successful conclusion of the EU post-authorization safety study (PASS) for Polyoxidonium ® in injections. The study confirmed its high tolerability and safety profile in patients.


In August, NPO Petrovax Pharm began exporting more than 2 million doses of the Grippol Plus ® flu vaccine to Kazakhstan. In October, a wide-spread free immunization campaign began in Belarus, for which the government procured Grippol Plus ® vaccine from NPO Petrovax Pharm.


In the middle of October the first batches of Metalize ®, a drug to treat acute myocardial infarction, became available to patients in Russia. Production was localized in Russia in partnership with Boehringer Ingelheim. At the end of the month, Petrovax Pharm received an ISO 9001:2015 management quality control system compliance certificate. In addition to the main ISO 9001:2015 certificate, Petrovax also obtained an IQNet single international certificate.


At the end of the year, the company donated 200 thousand doses of Grippol Plus® vaccine to clinics in the Moscow region to prevent flu epidemic.



Polyoxidonium ® won Russian Pharma Awards 2017, an annual competition held for the 6th time, in the «Drug of Choice to Prevent and Treat Acute Respiratory Infection and Flu in Children» category.

More
History
2018
In 2018 year
a new Grippol® Quadrivalent vaccine will be launched

In February 2018, NPO Petrovax Pharm received an award for «Dynamic Business Development» from the Russian Union of Industrialists and Entrepreneurs. The same month, Boehringer Ingelheim and Petrovax Pharm completed another phase in the process to begin domestic production of advanced thrombolytic drugs in Russia. The first supplies of Aktilise® for treatment of ischemic strokes have been delivered to Russian clinics.

In May 2018, Polyoxidonium won the Smartpharma Awards 2018. It received more votes than any other product in the category «Recommendation of the Year for Treatment of Acute Respiratory Infection and Flu in Children 3 years and older», putting it in first place.

In July, NPO Petrovax Pharm obtained a registration certificate to sell Grippol®Quadrivalent, the first quadrivalent influenza vaccine in Russia. This is the most advanced of the existing flu vaccines in the world, both highly effective and safe. The vaccine offers protection from four strains of influenza.

In September, NPO Petrovax pharmaceutical complex produced the first batch of preservatives-free, single-use Grippol®Quadrivalent vaccine syringes in accordance with the GMP standards, and thus marked the company’s tenth anniversary. Petrovax also launched the third production line for the manufacture of pills, suppositories and substances.

In November, Petrovax Pharm won PRIORITY-2018, the national award on import substitution, for the company’s contribution towards the creation and introduction of the Grippol®Quadrivalent vaccine into wide-spread healthcare practice in Russia. The very same month, at the Russian Pharma Awards, the VII national pharmaceutical award event, doctors voted for NPO Petrovax Pharm’s two products — Polyoxidonium® and Longidaza® — as the best medicines.

More
History
2019
RUB 1 bln per year - export volume to 11 countries
Overview
NPO Petrovax Pharm is a leading research and manufacturing company in Russia, producing pharmaceuticals and vaccines. NPO Petrovax Pharm brings its research developments to full-scale manufacturing in its state-of-the-art high-tech biopharmaceutical plants. The company’s manufacturing is in full compliance with the GMP EU and ISO:9001 international standards. The company’s product line consists exclusively of innovative drugs and vaccines that NPO Petrovax Pharm successfully markets in Russia and the countries of the CIS and the EU.
More
Press Center
The first place in the nomination «Medicine of choice for the treatment and prevention of SARS and influenza among children» was granted to «Polyoxidonium», produced by NGO Petrovax Pharm.
More
News
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
More
The event took place within the framework of the educational project «We and Media». Participants of the round table discussed ways of fighting dangerous infectious diseases and the role of the media in the popularization of the vaccine prophylaxis.
More
Events
At a conference on communication in the pharmaceutical industry, delegates discussed issues relevant to the pharmaceutical industry and emphasized the importance of open conversation and ongoing dialogue between the media and market experts.
More
NPO Petrovax Pharm passed an audit by the State Institute of Pharmaceuticals Quality Control of Slovakia, and was once again awarded the EU GMP production and quality management compliance certificate.
More
News
Interros Group is acquiring a controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company.  The parties signed the documents in Moscow today. Arkady Nekrasov and Natalia Puchkova, NPO Petrovax Pharm founders, will retain a stake in the company, and will continue to participate in business management. Financial terms of the deal are not disclosed.
More